PlainPharmaWatch

CMS Open Payments · Program Year 2024

Idorsia Pharmaceuticals US Inc

Idorsia Pharmaceuticals US Inc reported $1,829,196.86 in payments to 20,929 physicians and teaching hospitals across 21,025 transactions.

See the rankings → How this is sourced
$1.8M
Total payments
21,025
Transactions
20,929
Recipients
−$3.7M
General Payments vs PY2023

Idorsia Pharmaceuticals US Inc reported $1,829,196.86 in payments to 20,929 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #471 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $87.40 per recipient across 6 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Idorsia Pharmaceuticals US Inc pairs top-quartile payment volume with an unusually diversified payment pattern across a wide recipient base.

#471
of 1,925 companies
0.0%
of all US industry payments
0.0%
paid to its single top recipient
6
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Idorsia Pharmaceuticals US Inc's CMS-reported General Payments decreased by $3.7M (−75.5%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: IDORSIA PHARMACEUTICALS US INCPY2023: IDORSIA PHARMACEUTICALS US INCPY2024: IDORSIA PHARMACEUTICALS US INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$4.9MPY2024$1.2M
PY2023
$4,934,510.02
PY2024
$1,211,013.45

How Idorsia Pharmaceuticals US Inc ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Idorsia Pharmaceuticals US Inc's total vs. every reporting company

CMS Open Payments, Program Year 2024

$1,829,197 Top 24% higher than 76% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Idorsia Pharmaceuticals US Inc

Idorsia Pharmaceuticals US Inc ranks #471 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $1,829,196.86 across 21,025 transactions to 20,929 physicians and teaching hospitals - $87.00 per transaction and $87.40 per recipient on average.

252 transactions worth $660.3K make "Compensation for Services Other Than Consulting" the top general-payment category in the 6-category breakdown below, 36.1% of the reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Compensation for Services Other Than Consulting" leads Idorsia Pharmaceuticals US Inc's 6-category general-payment breakdown at $660.3K, 36.1% of the reported total.

How Idorsia Pharmaceuticals US Inc divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$660.3K2. Food and Beverage$431.3K3. Travel and Lodging$86.8K4. Consulting Fee$24.8K5. Grant$5.0K6. Education$2.8K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $660.3K 252
Food and Beverage $431.3K 20,296
Travel and Lodging $86.8K 318
Consulting Fee $24.8K 14
Grant $5.0K 1
Education $2.8K 48

Recipient Concentration in General Payments

The five largest recipient relationships account for $162,126.84 (13.4%) of $1,211,013.45 in this company's General Payments records across 11,919 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Idorsia Pharmaceuticals US Inc

The five named recipients with the highest reported General Payments from this company

Domingo Rodriguez-Cue$37.5KAlon Avidan$34.2KGreg L Friedman$31.9KVikas Jain$30.5KMichael Weber$28.0K
  1. 1

    Domingo Rodriguez-Cue

    $37,458.82 across 67 reported transactions

  2. 2

    Alon Avidan

    $34,238.11 across 35 reported transactions

  3. 3

    Greg L Friedman

    $31,932.91 across 88 reported transactions

  4. 4

    Vikas Jain

    $30,478.21 across 34 reported transactions

  5. 5

    Michael Weber

    $28,018.79 across 11 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $87.00. Average per recipient: $87.40.

Total Amount

$1,829,196.86

Avg per Transaction

$87.00

Avg per Recipient

$87.40

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Idorsia Pharmaceuticals US Inc Share

0.0%

#471 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Idorsia Pharmaceuticals US Inc

Guerbet LLC

$1.8M 368 recipients

XVIVO Perfusion Inc.

$1.8M 141 recipients

MDD US Operations, LLC

$1.8M 11,285 recipients

Ferring Pharmaceuticals AS

$1.8M 83 recipients

Merck Healthcare KGaA

$1.8M 36 recipients

A-dec, Inc.

$1.8M 7,139 recipients

Frequently Asked Questions

How much did Idorsia Pharmaceuticals US Inc pay to physicians and hospitals in 2024? ▾
Idorsia Pharmaceuticals US Inc made $1,829,196.86 in payments to physicians and hospitals in Program Year 2024, across 21,025 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Idorsia Pharmaceuticals US Inc? ▾
Idorsia Pharmaceuticals US Inc made payments to 20,929 physicians and teaching hospitals in 2024. The average payment per recipient was $87.40.
What types of payments did Idorsia Pharmaceuticals US Inc make? ▾
General payments from Idorsia Pharmaceuticals US Inc span 6 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Compensation for Services Other Than Consulting" at $660.3K, representing 36.1% of the company's reported total.
How does Idorsia Pharmaceuticals US Inc rank among pharmaceutical companies? ▾
Idorsia Pharmaceuticals US Inc ranks #471 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from Idorsia Pharmaceuticals US Inc? ▾
The average transaction from Idorsia Pharmaceuticals US Inc was $87.00 in 2024. The company made 21,025 total transactions to 20,929 recipients.
Where does the payment data for Idorsia Pharmaceuticals US Inc come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Idorsia Pharmaceuticals US Inc's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.